Secondary analysis of 120 patients with CMML randomised to decitabine or hydroxyurea: persistent monocytes >1x10^9/L or WBC >10x10^9/L after 6 cycles was linked to higher risk of death (HR 5.38) irrespective of treatment.
Secondary analysisn = 120
Selimoglu-Buet et al. Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?